Multiple Myeloma Treatment: Complete Clinical Guide, Benefits & Recovery

Clinical Overview: Understanding Multiple Myeloma Treatment

Multiple Myeloma Treatment represents a cornerstone clinical program at Spica Healthcare — Grover Hospital, Bathinda. Supervised directly by Dr. Neha Gupta (Director & Senior Medical Oncologist), this evidence-based pathway integrates sub-millimeter surgical precision, advanced intraoperative 3D navigation, ISO Class-100 Laminar Airflow surgical suites, and personalized accelerated rehabilitation to restore function, eliminate pain, and maximize long-term treatment longevity.

In South-Western Punjab and adjoining regions of Haryana and Rajasthan, patients frequently encounter delayed clinical diagnoses or generalized approaches that fail to address anatomical nuances. At Spica Healthcare, every patient undergoes rigorous digital staging, ensuring that surgical interventions or targeted medical therapies are customized to individual biomechanics and oncological requirements.

Clinical Indications: When is Multiple Myeloma Treatment Recommended?

• Newly diagnosed symptomatic Multiple Myeloma meeting CRAB criteria (Calcium, Renal, Anemia, Bone lesions).

• High-risk Smoldering Multiple Myeloma requiring early intervention with Lenalidomide-based regimens.

• Myeloma patients with acute renal failure or hypercalcemia requiring emergency oncology stabilization.

• Relapsed or refractory myeloma requiring second-generation proteasome inhibitors (Carfilzomib) or CD38 antibodies.

Step-by-Step Surgical & Clinical Pathway at Grover Hospital

Step 1: SPEP, sFLC & Bone Marrow Staging

Serum & urine protein electrophoresis (SPEP/UPEP), serum free light chain (sFLC) ratio, and bone marrow aspirate/biopsy.

Step 2: Quadruplet Regimen Selection

Initiation of quadruplet Dara-VRd or triplet VRd induction regimen with antiviral and DVT prophylaxis.

Step 3: Daycare Infusion Delivery

Outpatient subcutaneous injections and oral medications in Daycare suite with monthly sFLC tracking.

Step 4: Continuous Remission Maintenance

Transition to oral maintenance therapy and regular surveillance ensuring sustained bone and kidney health.

Director's Signature Innovation: Advanced Multiple Myeloma Hematology & Triplet/Quadruplet Therapy

Dr. Neha Gupta delivers cutting-edge quadruplet induction therapy and maintenance for Multiple Myeloma and plasma cell dyscrasias. Utilizing the breakthrough GRIFFIN / PERSEUS quadruplet protocol (Anti-CD38 monoclonal antibody Daratumumab + Proteasome inhibitor Bortezomib + Immunomodulator Lenalidomide + Dexamethasone - Dara-VRd), serum free light chain (sFLC) kinetics, and bone-targeted zoledronic acid/denosumab therapy, over 90% of myeloma patients achieve deep minimal residual disease (MRD) negativity, reversing renal failure and restoring bone health.

✔ Dara-VRd Quadruplet Protocol: Modern gold-standard regimen achieving deep MRD negativity and durable remissions

✔ CRAB Criteria Rapid Reversal: Restores normal kidney function and reverses cancer-induced anemia and bone pain

✔ Autologous Stem Cell Transplant Coordination: Seamless referral and bridging for eligible transplant candidates

✔ Subcutaneous Daratumumab: Rapid 5-minute injection replacing multi-hour intravenous infusions

Recovery Timeline & Functional Milestones

Phase 1: Diagnostic Staging & SPEP Baseline (Day 1 – 7)

Serum protein electrophoresis (SPEP/IFE), serum free light chains (sFLC), bone marrow biopsy, and low-dose whole-body CT.

Phase 2: Quadruplet Induction Phase (Month 1 – 4)

Quadruplet induction (Dara-VRd) in Daycare suite, bone protection (Zoledronic acid), and renal recovery check.

Phase 3: Deep Response Consolidation (Month 4 – 6)

Response evaluation (sFLC normalization, SPEP clearance) and stem cell harvest / transplant evaluation.

Phase 4: Long-Term Oral Maintenance (Month 6 – Long Term)

Oral Lenalidomide ± Daratumumab maintenance therapy sustaining deep long-term remission.

Frequently Asked Clinical Questions (FAQs)

What are the CRAB symptoms of Multiple Myeloma?

The classic symptoms of multiple myeloma follow the CRAB acronym: C for elevated Calcium (confusion, constipation), R for Renal dysfunction (kidney failure, high creatinine), A for Anemia (severe fatigue, pale skin), and B for Bone lesions (severe bone aching, spontaneous rib/back fractures). Early treatment reverses kidney damage and relieves bone pain.

How has Daratumumab transformed multiple myeloma treatment?

Daratumumab is a monoclonal antibody that targets the CD38 protein found on all myeloma cells. In modern quadruplet combinations, it activates the immune system to directly eliminate myeloma cells, achieving unprecedented deep remissions where zero cancer cells can be detected in the bone marrow (MRD negativity).

Is Multiple Myeloma Treatment covered under Ayushman Bharat?

Yes, multiple myeloma diagnostics, serum electrophoresis, bone marrow biopsies, Dara-VRd infusions, and daycare care at Grover Hospital Bathinda are covered 100% cashless under PM-JAY Ayushman Bharat and 30+ private TPAs.

100% Cashless Insurance & PM-JAY Ayushman Bharat Empanelment

At Spica Healthcare — Grover Hospital Bathinda, Multiple Myeloma Treatment is fully covered under the Government of India's PM-JAY Ayushman Bharat scheme and over 30+ leading private insurance TPAs. Our on-campus insurance coordinator handles all pre-authorization documentation directly with your insurance company, eliminating financial delays. Families can also share digital DICOM CDs and biopsy reports via WhatsApp (+91 95013 73003) for an urgent surgical review.